Exporting Cannabis to Israel from Canada in 2026: What Licensed Producers Need to Know

Israel Ranks Among the World's Most Active Medical Cannabis Import Markets

Israel's Israel Medical Cannabis Agency (IMCA) authorised imports from 11 countries in 2024. Canada was the top source nation by volume, accounting for roughly 40% of all licensed cannabis flower imported that year. For Canadian Licensed Producers with strong quality documentation and consistent genetics, the Israeli pharmaceutical distribution channel is one of the most accessible premium markets in the world.

This guide covers what Canadian LPs need to know about exporting to Israel in 2026: the regulatory framework under IMCA, the IMC-GAP and IMC-GMP standards, the import permit process, what Israeli pharmaceutical distributors evaluate in a supply partner, and how to position your batch documentation to pass the Israeli compliance review on a first submission.

The IMCA Regulatory Framework: How Israel Controls Medical Cannabis Imports

Israel operates one of the most structured medical cannabis regulatory regimes outside the EU. The IMCA oversees both domestic cultivation and imports under the Dangerous Drugs Ordinance. All imported cannabis must be accompanied by a valid export permit from the country of origin and an IMCA import licence held by an Israeli-licensed importer.

Unlike the Australian ODC system, where permits are shipment-specific, the IMCA issues supply agreements that cover multiple shipments from a single approved supplier. This means the upfront qualification process is more demanding, but once approved, ongoing logistics are significantly smoother. The practical implication: invest heavily in the initial documentation package, because it determines your access for the duration of the supply agreement.

Under the International Narcotics Control Board (INCB) framework, both Canada and Israel are parties to the Single Convention on Narcotic Drugs. This creates the bilateral treaty foundation that makes licensed trade possible. Your Health Canada export permit under the Cannabis Act satisfies the Canadian side. The Israeli importer's IMCA licence satisfies the Israeli side.

IMC-GAP and IMC-GMP: What Israel Requires from a Canadian Supplier

Israel has developed its own cultivation and manufacturing standards: IMC-GAP (Good Agricultural Practice) and IMC-GMP (Good Manufacturing Practice). These are not identical to Health Canada's Good Production Practices, but they share substantial common ground. Most Canadian LPs producing under GPP can demonstrate IMC-GMP alignment without structural process changes.

The key areas where Israeli standards require specific documentation from Canadian suppliers:

• Cultivation conditions: IMC-GAP requires disclosure of growing medium, lighting type, pest management protocols, and harvest method. Indoor cultivation with documented environmental controls maps cleanly to IMC-GAP. Hand-trimming is a positive differentiator. Israeli distributors consistently ask about trim method in their supplier questionnaires.
• Testing panel and laboratory accreditation: IMCA requires a full cannabinoid and terpene panel, heavy metals, pesticide residues, microbial contamination, and mycotoxins. Your testing laboratory must be ISO/IEC 17025-accredited. Certificates from non-accredited labs are rejected without review.
• Batch traceability: IMCA requires a seed-to-shipment traceability record for every batch. This means your production records, harvest data, drying logs, and COA must link to a single traceable batch identifier. If your internal documentation does not already produce a consolidated traceability package, this is the first gap to close.
• Stability and shelf-life data: Unlike Health Canada GPP, IMCA requests shelf-life validation data or a minimum stability study summary. This is one of the more common documentation gaps for Canadian LPs entering the Israeli market for the first time.

LPs without shelf-life data on file should not wait to start the Israel qualification process. A 6-month accelerated stability study can run concurrently with the initial distributor outreach. Waiting until an importer asks for it adds months to your timeline unnecessarily.

The Israel Import Permit Process: Step by Step

Here is the Canada-Israel Medical Cannabis Supply Path, as it typically runs for a first approved supply relationship:

1. Identify a licensed Israeli importer. IMCA publishes a list of licensed importers on its portal. Your Israeli distribution partner must hold an active IMCA import licence. Distributors without a current licence cannot initiate the permit process. Verify licence status before committing to a partnership.
2. Complete the supplier qualification package. Your Israeli importer submits a supplier qualification dossier to IMCA. This package typically includes: your Health Canada Standard Cultivation Licence, your GPP compliance certificate or audit summary, three consecutive batch COAs demonstrating consistency, your ISO/IEC 17025 lab accreditation certificate, and your shelf-life or stability data.
3. IMCA supplier approval. IMCA reviews the dossier and either approves the supplier or requests supplementary documentation. First-time approvals typically take 6-10 weeks. Incomplete submissions are the main cause of delays. A well-prepared dossier moves faster than average.
4. Health Canada export permit application. Once IMCA supplier approval is granted, apply to Health Canada for a batch-specific export permit under the Cannabis Regulations. Health Canada typically processes these within 10-20 business days.
5. IMCA import permit for the shipment. The Israeli importer applies for a shipment-specific import permit from IMCA once the export permit is in hand. Under an existing supply agreement, this step takes 5-7 business days.
6. Shipment and customs clearance. Both permits travel with the shipment. Israeli customs inspects documentation at the point of entry. Any mismatch between the permit details and the physical shipment results in a hold. Verify every field against the actual batch before dispatch.

Total timeline for a first approved shipment, from initial distributor contact to product in Israel, typically runs 14-20 weeks. The IMCA supplier approval process is the long pole. Everything after approval moves quickly.

What Israeli Pharmaceutical Distributors Look for in a Canadian LP

Israel's medical cannabis channel is pharmacy-dispensed. Patients receive prescriptions from physicians and fill them at licensed pharmacies. This means Israeli distributors are accountable to both IMCA and the Ministry of Health for the quality and consistency of every product they carry. Their supplier qualification standards reflect that accountability.

Four criteria appear in almost every Israeli distributor's supplier evaluation:

• Cannabinoid profile consistency: Israeli distributors track patient outcomes by strain. A THC variance of more than 10% batch-to-batch is enough for some distributors to decline a supply relationship, regardless of average potency. Genetics that produce narrow cannabinoid ranges are a genuine commercial advantage here.
• Terpene profile documentation: Israel's medical channel has moved faster than most markets toward terpene-forward product selection. Distributors want full terpene panel data on every batch, not just major cannabinoids. If your COA does not include a terpene panel, add it before approaching Israeli partners.
• Supply continuity: Israel's patient population is chronic, not episodic. Distributors need predictable volume quarter-over-quarter. LPs unable to commit to multi-quarter supply agreements are deprioritised in supplier selection, regardless of product quality.
• Responsive regulatory support: IMCA audits distributors and reviews their supplier documentation on an ongoing basis. When IMCA requests supplementary data from a distributor about their Canadian supplier, a 24-48 hour response time is expected. LPs who treat post-approval documentation requests as low priority create problems for their distribution partners. Those relationships do not survive a second IMCA audit cycle.

Israeli distributors are not buying flower. They are buying a documented, consistent, defensible supply that survives regulatory scrutiny. The suppliers who succeed in this market are the ones who treat compliance documentation as a product feature, not an afterthought.

What AlphaLeaf Brings to the Israeli Medical Cannabis Channel

AlphaLeaf is a Montreal-based Health Canada Licensed Producer specialising in indoor-grown, hand-trimmed cannabis flower. We hold export authorisation under the Cannabis Act and maintain full batch traceability, ISO/IEC 17025-accredited testing, and GPP-aligned production documentation aligned with IMC-GMP requirements. Our flagship cultivar, Ice Cream Cake (30.3% THC, large-bud format, hand-trimmed), produces the consistent cannabinoid and terpene profiles that Israeli pharmaceutical distributors require for patient-facing supply. To discuss a supply relationship for the Israeli medical channel, contact us at alphaleaf.ca/#contact or review our compliance documentation at alphaleaf.ca/#certifications. For more on our export markets, visit alphaleaf.ca/#international.

Frequently Asked Questions

Does Canada export cannabis to Israel?

Yes. Canada is the top source country for medical cannabis imported into Israel, accounting for approximately 40% of licensed imports by volume in 2024. Canadian LPs with a valid Health Canada export permit can supply Israeli-licensed importers under the IMCA framework, provided the supplier has been approved in IMCA's supplier qualification process.

What is IMC-GMP and does it apply to Canadian LP exports?

IMC-GMP is Israel's Good Manufacturing Practice standard for medical cannabis, developed by the Israel Medical Cannabis Agency. Canadian LPs producing under Health Canada's GPP framework generally meet IMC-GMP requirements, with the main documentation gap typically being shelf-life or stability data, which IMC-GMP specifically requires and Health Canada GPP does not mandate.

How long does it take to get IMCA supplier approval?

First-time IMCA supplier approvals typically take 6-10 weeks from submission of a complete dossier. Incomplete submissions are the most common cause of delays. Once supplier approval is granted, individual shipment permits take 5-7 business days under an active supply agreement. Total first-shipment timeline from initial distributor contact to product in Israel is typically 14-20 weeks.

What documents does a Canadian LP need to export cannabis to Israel?

The IMCA supplier qualification dossier typically requires: your Health Canada Standard Cultivation Licence, a GPP compliance certificate or audit summary, three consecutive batch COAs demonstrating consistency, ISO/IEC 17025 lab accreditation certificate, and stability or shelf-life data. Each shipment also requires a batch-specific Health Canada export permit and a shipment-specific IMCA import permit held by the Israeli importer.

Do Israeli distributors require terpene panel data from Canadian suppliers?

Yes. Israel's medical cannabis channel has moved toward terpene-forward product selection faster than most markets. Full terpene panel data on every batch is increasingly standard in Israeli distributor supplier questionnaires, not an optional enhancement. COAs that report only major cannabinoids without a terpene panel put a Canadian supplier at a disadvantage in the Israeli qualification process.

How is the Israeli import process different from the Australian ODC process?

The key difference is in permit scope. Australia's ODC issues shipment-specific import permits, meaning each new shipment requires a new permit application. Israel's IMCA operates through supply agreements that cover multiple shipments from an approved supplier, making ongoing logistics smoother once initial supplier approval is granted. The Israeli upfront qualification process is more demanding, particularly around stability data and consistency documentation, but approval unlocks a more streamlined ongoing supply relationship.